Charlie Lees
3y ago
I write about Crohn's disease and ulcerative colitis (IBD), digital health, diet, genetics and the microbiome. I am a passionate educator and innovator. I am a gastroenterologist and I run a busy IBD clinic. I am a Professor of Gastroenterology running a research team improving outcomes for people living with IBD. For more content please see charlielees.com and search Charlie Lees at YouTube.
Current monitoring systems for IBD work well, but have some limitations.
No one tool is sufficient. We rely on a combination of invasive and non-invasive tests that provide assessment of symptoms plus mucosal and systemic inflammation.
Here are just some of the problems with each testing modality:
Symptoms are unreliable and correlate poorly with gut inflammation
Continuous collection of symptoms (eg by daily recording in an app) will only work for the short to medium term, even for the most dedicated patients
Blood tests require a visit to a clinic and are limited in the information they provide for most patients, most of the time
Calprotectin is fiddly to collect, is subject to daily variation and lacks specificity
Small bowel MRI scanning requires ingestion of unpalatable bowel distending agents and capacity is often limited
Intestinal ultrasound is operator dependent and currently only available in limited centers
Colonoscopy is invasive and requires full bowel prep
With these tests we are limited in our ability to robustly monitor entire populations in a manner that will continuously maintain deep remission.
Next time we'll look to future systems that will radically improve outcomes.